Revelation Biosciences (REVB)
NASDAQ:REVB
Want to see REVB full AI Analyst Report?
Top Page
Revelation Biosciences
(NASDAQ:REVB)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.00
▲(11.11% Upside)
Action:ReiteratedDate:03/20/26
The score is primarily constrained by weak financial performance—no revenue, persistent losses, and accelerating cash burn—raising ongoing funding risk. Technicals are also unfavorable with a clear downtrend and negative momentum indicators, despite oversold readings. Valuation provides limited support due to negative earnings and no dividend yield.
Positive Factors
Targeted innate-immunity pipeline
A focused clinical-stage platform targeting innate immunity creates a durable strategic niche across respiratory viral infections and related indications. This platform orientation supports repeatable R&D application, potential multi-indication value capture, and clearer prioritization of clinical resources over the next 2–6 months.
Negative Factors
Pre-revenue profile
No product revenue leaves the company fully dependent on external capital to fund operations and trials. This structural reliance increases dilution and execution risk over time, reducing visibility into sustainable cash generation and making long-term planning contingent on successful raises or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted innate-immunity pipeline
A focused clinical-stage platform targeting innate immunity creates a durable strategic niche across respiratory viral infections and related indications. This platform orientation supports repeatable R&D application, potential multi-indication value capture, and clearer prioritization of clinical resources over the next 2–6 months.
Read all positive factors
Revelation Biosciences (REVB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.69M
Dividend YieldN/A
Average Volume (3M)740.56K
Price to Earnings (P/E)―
Beta (1Y)0.58
Revenue GrowthN/A
EPS Growth96.26%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.65
Shares Outstanding3,720,420
10 Day Avg. Volume239,834
30 Day Avg. Volume740,557
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit972.94
Enterprise Value/Ebitda0.63
Forecast
1Y Price Target
$16.00Price Target Upside1677.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-14.32
Revenue Forecast (FY)N/A
Revelation Biosciences Business Overview & Revenue Model
Company Description
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, inclu...
How the Company Makes Money
null...
Revelation Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.06K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -9.04M | -7.95M | -8.63M | -10.84M | -11.93M |
| Net Income | -8.91M | -15.04M | -120.25K | -10.83M | -11.99M |
Balance Sheet | |||||
| Total Assets | 11.58M | 6.62M | 12.21M | 5.50M | 2.04M |
| Cash, Cash Equivalents and Short-Term Investments | 10.70M | 6.50M | 11.99M | 5.25M | 1.27M |
| Total Debt | 746.78K | 0.00 | 0.00 | 0.00 | 16.75K |
| Total Liabilities | 2.72M | 1.91M | 5.56M | 4.45M | 2.14M |
| Stockholders Equity | 8.86M | 4.71M | 6.65M | 1.05M | -99.47K |
Cash Flow | |||||
| Free Cash Flow | -8.27M | -18.34M | -7.29M | -11.22M | -11.22M |
| Operating Cash Flow | -8.27M | -18.32M | -7.29M | -11.22M | -11.09M |
| Investing Cash Flow | 0.00 | -19.17K | 0.00 | 0.00 | -131.96K |
| Financing Cash Flow | 12.47M | 12.85M | 14.03M | 15.20M | 8.00M |
Revelation Biosciences Technical Analysis
Negative
0.90
Price Trends
1.29
Negative
2.34
Negative
5.12
Negative
Market Momentum
-0.05
Negative
40.55
Neutral
62.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REVB, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 1.19, below the 50-day MA of 1.29, and below the 200-day MA of 5.12, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 40.55 is Neutral, neither overbought nor oversold. The STOCH value of 62.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for REVB.
Revelation Biosciences Risk Analysis
Revelation Biosciences disclosed 65 risk factors in its most recent earnings report. Revelation Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Revelation Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $5.07M | -0.28 | -203.36% | ― | ― | 90.53% | |
43 Neutral | $12.24M | -0.15 | -356.99% | ― | ― | 54.62% | |
43 Neutral | $3.56M | -0.12 | -215.04% | ― | -100.00% | 93.82% | |
42 Neutral | $4.69M | -0.22 | -0.40% | ― | ― | 96.26% |
* Healthcare Sector Average
REVB
Revelation Biosciences
1.15
-35.82
-96.90%
GTBP
GT Biopharma
0.38
-1.79
-82.53%
DRMA
Dermata Therapeutics
1.36
-5.71
-80.76%
CERO
CERo Therapeutics Holdings
0.03
-12.31
-99.76%
PBM
Psyence Biomedical
7.60
-14.22
-65.17%
AZTR
Azitra Inc
0.21
-1.68
-88.72%
Revelation Biosciences Corporate Events
Private Placements and FinancingShareholder Meetings
Revelation Biosciences Shareholders Approve Warrant Share Issuance
Positive
Mar 19, 2026
On March 18, 2026, Revelation Biosciences held a Special Meeting of Stockholders at which investors approved the issuance of common shares underlying the Class J Common Stock Warrants, even if such issuance exceeds 20% of outstanding shares and wo...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Revelation Biosciences Raises Capital via Warrant Inducement
Positive
Jan 29, 2026
On January 23, 2026, Revelation Biosciences entered into inducement agreements with two holders of its existing Class I common stock warrants, leading to the immediate cash exercise of 8,544,999 pre-split (2,136,251 post-split) warrants at an effe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.